News

Deal Announcements

Calistoga Pharmaceuticals Nets $21 Million Round

Tuesday, March 6, 2007 7:30:00 AM PDT | VentureDeal Staff
SEATTLE, WA -- Calistoga Pharmaceuticals announced that it had raised $21 million in new investment from several venture capital firms.

The company is a spin-off from Icos Corp, which was acquired by Eli Lilly (NYSE: LLY) in January.  Calistoga is developing a drug candidate acquired from Icos that can potentially treat various types of cancer.

Investors in the round included lead investor Frazier Healthcare Ventures, Alta Partners, Three Arch Partners and Amgen Ventures, the corporate venturing arm of Amgen Corporation.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1